ERCC4 and cancer: Additionally, we provided a set of commercially available compounds, which can potentially bind to the XPF catalytic site and inhibit the endonuclease activity of ERCC1-XPF; therefore, they can be considered in combination with DNA-damaging cancer therapies to amplify their effects.